The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Targeting angiogenesis driven by fibroblast growth factor using RPT835, an FGFR2 inhibitor.
Evgenia Stepanova
No relevant relationships to disclose
Eliso Solomko
No relevant relationships to disclose
Oxana Ryabaya
No relevant relationships to disclose
Nina Peretolchina
No relevant relationships to disclose
Ilya Tsimafeyeu
No relevant relationships to disclose
Sergei Tjulandin
No relevant relationships to disclose